Evidence map›Paper›PMID 40821428›Full record

ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025

Myalgia and Rigidity as Adverse Effects of Trametinib Therapy.

Charles J Weeks, Victoria Frame, Rohan Vuppala, David Thomas, Abigayle B Simon, Michael Stokes, Colleen McDonough

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Charles J WeeksSchool of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia.
Victoria FrameSchool of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia.
Rohan VuppalaSchool of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia.
David ThomasSchool of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia.
Abigayle B SimonSchool of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia.
Michael StokesSchool of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia.
Colleen McDonoughSchool of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitogen-activated extracellular kinase inhibitors, including trametinib and selumetinib, are increasingly used to treat pediatric low-grade gliomas. Trametinib, while administered orally and with minimal myelosuppression, is reported to cause rash, diarrhea, and fatigue. Selumetinib has been associated with skin irritation, diarrhea, and musculoskeletal pain. This case report describes an 8-month-old male with a low-grade glioma (LGG) that progressed 6 months post-chemotherapy and was started on trametinib due to its liquid formulation and minimal side effect profile. However, the patient developed severe diarrhea, abdominal pain, neck pain, rigidity, and decreased stamina. These symptoms necessitated discontinuation of trametinib, after which all symptoms resolved within a week. This case highlights the first reported instance of trametinib-induced myalgia and rigidity in a pediatric patient receiving trametinib therapy for a LGG. Clinicians should consider these rare but significant adverse effects when choosing an antineoplastic therapy for the treatment of progressive LGG.

Indexed as

case reportsGliomasMEK inhibitormyalgiaside effects of drugstrametinib

Identifiers

PMID40821428
PMCPMC12351478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.